Notice of Results

RNS Number : 1978U

ReNeuron Group plc

19 June 2009

 



PRESS RELEASE

Notification of Results 

Guildford, UK, 19 June 2009: ReNeuron Group plc (LSE: RENE.L) will be announcing its results for the year ended 31 March 2009 on Tuesday 30 June 2009.  

There will be a presentation to analysts on the day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB. 

Enquiries:

ReNeuron 

Michael Hunt, Chief Executive Officer

Tel: [phone]

Financial Dynamics

Juliet Edwards

Tel: [phone]

About ReNeuron

ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron recently received regulatory approval to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX
and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

NORFKLFFKQBFBBQ